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Adrenergic Mediation of Hypoglycemia-Associated
Autonomic Failure
Ranjani Ramanathan and Philip E. Cryer
OBJECTIVE—We tested the hypothesis that adrenergic activa-
tion, cholinergic activation, or both, mediate the effect of recent
antecedent hypoglycemia to reduce the sympathoadrenal response
to subsequent hypoglycemia, the key feature of hypoglycemia-
associated autonomic failure in diabetes, in humans.
RESEARCH DESIGN AND METHODS—Seventeen healthy
adults were studied on 2 consecutive days on three occasions.
Day 1 involved hyperinsulinemic euglycemic (90 mg/dL 3 1 h),
then hypoglycemic (54 mg/dL 3 2 h) clamps, in the morning
and afternoon on all three occasions with 1) saline infusion,
2) adrenergic blockade with the nonselective a-adrenergic and
b-adrenergic antagonists phentolamine and propranolol, or 3)
adrenergic blockade plus cholinergic blockade with the musca-
rinic cholinergic antagonist atropine in random sequence. Day 2
involved similar morning euglycemic and hypoglycemic clamps,
with saline infusion, on all three occasions.
RESULTS—Compared with the responses to hypoglycemia
during saline infusion on day 1, the plasma epinephrine and
norepinephrine responses to hypoglycemia were reduced on day
2 (351 6 13 vs. 214 6 22 pg/mL for epinephrine and 252 6 4 vs.
226 6 7 pg/mL for norepinephrine during the last hour; both P ,
0.0001). However, the plasma epinephrine and norepinephrine
responses to hypoglycemia were not reduced on day 2 when
adrenergic or adrenergic plus cholinergic blockade was pro-
duced during hypoglycemia on day 1.
CONCLUSIONS—Adrenergic blockade prevents the effect of
hypoglycemia to reduce the plasma catecholamine responses to
subsequent hypoglycemia. Thus, adrenergic activation mediates
the effect of recent antecedent hypoglycemia to reduce the
sympathoadrenal response to subsequent hypoglycemia, the key
feature of hypoglycemia-associated autonomic failure in diabe-
tes, in humans. Diabetes 60:602–606, 2011
I
atrogenic hypoglycemia is the limiting factor in the
glycemic management of diabetes (1). It causes re-
current morbidity in most people with type 1 di-
abetes and in many with type 2 diabetes, and is
sometimes fatal, impairs physiologic and behavioral de-
fenses against subsequent hypoglycemia, and generally
precludes maintenance of euglycemia over a lifetime of
diabetes. The concept of hypoglycemia-associated auto-
nomic failure (HAAF) in diabetes posits that recent ante-
cedent hypoglycemia, as well as prior exercise or sleep,
causes both the syndrome of defective glucose counter-
regulation (by reducing the adrenomedullary epinephrine
response to subsequent hypoglycemia in the setting of
absent decrements in insulin and absent increments in
glucagon) and of hypoglycemia unawareness (by reducing
the sympathoadrenal and resulting neurogenic symptom
responses to subsequent hypoglycemia) (1–4). These two
components of HAAF are both associated with a sub-
stantially increased incidence of hypoglycemia during
intensive therapy for diabetes (1). Perhaps the most com-
pelling evidence of the clinical effect of HAAF is the ﬁnding,
originally in three independent laboratories (5–8), that as
little as 2 to 3 weeks of scrupulous avoidance of hypogly-
cemia reverses hypoglycemia unawareness and improves
the attenuated epinephrine component of defective glucose
counterregulation in most affected patients.
The mechanisms of the attenuated sympathoadrenal
response to hypoglycemia, the key feature of the patho-
genesis of HAAF in diabetes (1–8), are unknown (1). Al-
though much of the neuroscience research into this issue
has focused on the hypothalamus (9), recent translational
research has raised the possibility that a complex cerebral
network normally regulates the hypothalamic (and thus
the systemic sympathoadrenal) response to falling plasma
glucose concentrations (10–12) and that an inhibitory
signal mediated through the thalamus might be involved in
the pathogenesis of HAAF (12).
Hypoglycemia activates the sympathoadrenal system
(1,13,14). This includes the release of catecholamines that
interact with a-adrenergic and b-adrenergic receptors—
norepinephrine from sympathetic postganglionic neurons
and epinephrine and norepinephrine from the adrenal
medullae—and acetylcholine that interacts with muscarinic
cholinergic receptors—from sympathetic postganglionic
neurons. Hypoglycemia also activates central nervous sys-
tem circuits, including those that involve adrenergic and
cholinergic neurotransmission. There are, of course, an
array of other neurotransmitters released in the peripheral
and the central nervous systems.
We used the original model of HAAF (2) and the nonse-
lective a-adrenergic and b-adrenergic antagonists phentol-
amine and propranolol as well as the muscarinic cholinergic
antagonist atropine in doses shown previously to be both
safe and effective (15) to test the hypothesis that ad-
renergic activation, cholinergic activation, or both, me-
diate the effect of recent antecedent hypoglycemia to
reduce the sympathoadrenal response to subsequent hy-
poglycemia, the key feature of HAAF in diabetes (1–8), in
humans.
RESEARCH DESIGN AND METHODS
This study was approved by the Washington University Human Research
Protection Ofﬁce and was conducted at the Washington University Clinical
Research Unit (CRU).
Participants. Study participants comprised 17 adults (7 women, 10 men), with
a mean (6 SD) age of 29 6 5 years and a BMI of 26.5 6 4.6 kg/m
2, who gave
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ORIGINAL ARTICLEtheir written consent. They were in good health as determined by medical
history, physical examination, and fasting plasma glucose and creatinine
concentrations, hematocrits, and electrocardiograms that were within normal
reference ranges.
Experimental design. Participants were studied on 2 consecutive days on
three occasions, separated by at least 2 weeks, after overnight fasts. In-
travenous catheters were inserted into a hand vein, with that hand kept in a
;55°C plexiglas box for arterialized venous blood sampling, and into a con-
tralateral antecubital vein for insulin, glucose, and drug infusions and injections.
Day 1 involved hyperinsulinemic (2.0 mU/kg/min), euglycemic (90 mg/dL
[5.0 mmol/L] 3 1 h), and then hypoglycemic (54 mg/dL [3.0 mmol/L] 3 2h )
clamps in the morning and again in the afternoon on all three occasions. In-
travenous infusions during these day 1 glucose clamps were 1) saline, 2)t h e
nonselective a-adrenergic receptor antagonist phentolamine mesylate (70
mg/kg, followed by 7.0 mg/kg/min) and the nonselective b-adrenergic antag-
onist propranolol hydrochloride (14 mg/kg, followed by 1.4 mg/kg/min), or
3) phentolamine plus propranolol and the muscarinic cholinergic antagonist
atropine (1.0 mg injected intravenously at the end of each euglycemic clamp
and 60 min into each hypoglycemic clamp) in random sequence. This exper-
imental design is illustrated, with the actual plasma glucose concentration
data, in Fig. 1.
Plasma glucose concentrations were measured every 5 min at the bedside
(YSI Glucose Analyzer, Yellow Springs Instruments, Yellow Springs, OH) to
guide 20% glucose infusions. Heart rates and blood pressures (GE Dash 3000,
Fairﬁeld,CT)wererecordedat15-minintervals,andtheelectrocardiogramwas
monitored throughout. Arterialized venous samples for the additional analytes
detailed below were drawn at 15-min intervals during the morning euglycemic
and hypoglycemic clamps on both days. This model of morning and afternoon
hypoglycemia reduces the sympathoadrenal response to hypoglycemia the
following day (1–4), and these doses of phentolamine, propranolol, and atro-
pine are safe and hemodynamically, metabolically, and symptomatically ef-
fective (15).
Day 2 involved identical hyperinsulinemic euglycemic and then hypogly-
cemic clamps, with saline infusion, in the morning on all three occasions.
Arterialized venous samples were again used to measure plasma glucose
concentrations every 5 min and were drawn for the analytes detailed sub-
sequently every 15 min.
Analytic methods. Plasma glucose concentrations were measured with
a glucose oxidase method (YSI Glucose Analyzer). Plasma insulin, C-peptide,
growth hormone, and cortisol concentrations were measured with two site
chemiluminescent assays (Immulite 1000, Siemens Corp., Los Angeles, CA).
Plasma glucagon and pancreatic polypeptide concentrations were measured
with Linco radioimmunoassays (Millipore, Temecula, CA). Plasma epinephrine
and norepinephrine concentrations were measured with a single isotope-
derivative (radioenzymatic) method (16).
Statistical methods. Time and condition related variables were analyzed by
repeated measures mixed model ANOVA. Values of P , 0.05 were considered
to indicate statistically signiﬁcant differences. Data are expressed as the
mean 6 SE, except where the SD is indicated.
RESULTS
Plasma glucose concentrations, day 1 and day 2. Plasma
glucose concentrations were clamped at euglycemic
(;90 mg/dL [5.0 mmol/L]) and then hypoglycemic (;54
mg/dL [3.0 mmol/L]) levels in the morning and again in
the afternoon—with intravenous infusions of saline,
phentolamine plus propranolol (adrenergic blockade), or
phentolamine plus propranolol with injection of atropine
(adrenergic plus cholinergic blockade)—on day 1 and on
the morning of day 2—with intravenous infusion of saline—
after saline, phentolamine plus propranolol, or phentol-
amine plus propranolol with atropine on day 1 on three
separate occasions (Fig. 1). The glucose infusion rates re-
quired to maintain the clamps were similar on all occasions
(data not shown).
Responses on day 1. Compared with those during saline,
increments in plasma epinephrine and norepinephrine con-
centrations during hypoglycemia were increased about
threefold during adrenergic blockade and during adrener-
gic plus cholinergic blockade (both P , 0.0001; Fig. 2). The
ﬁnal epinephrine values were 352 6 46 pg/mL (1,920 6 251
pmol/L), 1,040 6 160 pg/mL (5,680 6 873 pmol/L), and
1,130 6 193 pg/mL (6,170 6 1,050 pmol/L), respectively.
The ﬁnal norepinephrine values were 257 6 19 pg/mL
(1.52 6 0.11 nmol/L), 809 6 84 pg/mL (4.78 6 0.50 nmol/L),
and 786 6 100 pg/mL (4.65 6 0.59 nmol/L), respectively.
Increments in plasma pancreatic polypeptide concen-
trations during hypoglycemia were similar during saline
and during adrenergic blockade but were prevented during
adrenergic plus cholinergic blockade. The ﬁnal pancreatic
polypeptide values were 356 6 45 pg/mL (85 6 11 pmol/L),
374 6 42 pg/mL (89 6 10 pmol/L), and 75 6 9 pg/mL
(18 6 2 pmol/L), respectively.
FIG. 1. Mean (SEs within the symbols) plasma glucose concentrations
are shown during morning and afternoon hyperinsulinemic euglycemic
and hypoglycemic clamps with intravenous infusions of saline (○),
phentolamine plus propranolol (PTL + PRP, □) or phentolamine plus
propranolol with injection of atropine (PTL + PRP + Atropine, △)o n
day 1 and during morning hyperinsulinemic euglycemic and hypoglyce-
mic clamps with intravenous infusion of saline on day 2 after saline (●),
PTL + PRP (■) or PTL + PRP + Atropine (▲) on day 1 on three sepa-
rate occasions.
FIG. 2. Mean (6 SE) plasma epinephrine, norepinephrine, and pan-
creatic polypeptide concentrations are shown during morning hyper-
insulinemic euglycemic and hypoglycemic clamps with intravenous
infusions of saline (○), phentolamine plus propranolol (PTL + PRP, □),
or phentolamine plus propranolol with atropine (△) on day 1. The P
values represent comparisons with the values during saline infusion
(both P < 0.0001) for epinephrine and norepinephrine and comparisons
with values during phentolamine plus propranolol with atropine (P <
0.0001) for pancreatic polypeptide.
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;95 mU/mL (570 pmol/L) during infusion of saline but rose
to ;120 mU/mL (720 pmol/L) during adrenergic blockade
and during adrenergic plus cholinergic blockade (both P ,
0.0001; Fig. 3). The ﬁnal insulin values were 96 6 8 mU/mL
(576 6 48 pmol/L), 122 6 12 mU/mL (732 6 72 pmol/L),
and 123 6 9 mU/mL (738 6 54 pmol/L), respectively.
Increments in plasma glucagon concentrations during hy-
poglycemia were similar on all three occasions (Fig. 3).
The ﬁnal glucagon values were 98 6 11 pg/mL (28 6
3 pmol/L), 110 6 10 pg/mL (32 6 3 pmol/L), and 104 6
7 pg/mL (30 6 2 pmol/L), respectively.
Compared with those during saline, increments in plasma
growth hormone and cortisol concentrations during hypo-
glycemia were increased during adrenergic blockade and
adrenergic plus cholinergic blockade (P , 0.0001 under
both conditions for both hormones; Fig. 3). The ﬁnal growth
hormone values were 13.3 6 2.2 ng/mL (587 6 97 pmol/L),
25.2 6 3.2 ng/mL (1,110 6 141 pmol/L), and 20.7 6 2.8 ng/mL
(914 6 124 pmol/L), respectively. The ﬁnal cortisol values
were 18.4 6 1.5 mg/dL (508 6 41 nmol/L), 22.1 6 1.4 mg/dL
(610 6 39 nmol/L), and 23.7 6 1.6 mg/dL (654 6 44 nmol/L),
respectively.
Heart rate responses to hypoglycemia were decreased
during adrenergic blockade and increased during adren-
ergic plus cholinergic blockade compared with those
during saline (both P , 0.0001; Table 1). Systolic and di-
astolic blood pressures were reduced during adrenergic
blockade and during adrenergic plus cholinergic blockade
(both P , 0.0001; Table 1).
Responses on day 2 compared with those during
saline on day 1. Compared with that during saline on
day 1, the increment in the plasma epinephrine concen-
tration during hypoglycemia was attenuated by ;50% on
day 2 (P , 0.0001; Fig. 4). The epinephrine values during
the last hour of hypoglycemia were 351 6 13 pg/mL (1920 6
71 pmol/L) and 214 6 22 pg/mL (1170 6 120 pmol/L),
respectively. In contrast, the increments in plasma epi-
nephrine during hypoglycemia were not reduced on day
2 after adrenergic blockade or adrenergic plus cholinergic
blockade on day 1 (Fig. 4). The epinephrine values during
the last hour of hypoglycemia were 359 6 26 pg/mL
(1,960 6 142 pmol/L) and 375 6 11 pg/mL (2,050 6
60 pmol/L), respectively.
Similarly, the increment in the plasma norepinephrine
concentration during hypoglycemia was attenuated on day
2 compared with that during saline on day 1 (P , 0.0001;
Fig. 4). The norepinephrine values during the last hour of
hypoglycemia were 252 6 4 pg/mL (1.49 6 0.02 nmol/L)
and 226 6 7 pg/mL (1.34 6 0.04 nmol/L), respectively. The
increments in plasma norepinephrine during hypoglycemia
were not reduced on day 2 after adrenergic blockade
or adrenergic plus cholinergic blockade on day 1 (Fig. 4).
The norepinephrine values during the last hour of hypo-
glycemia were 284 6 11 pg/mL (1.68 6 0.06 nmol/L) and
256 6 11 pg/mL (1.51 6 0.06 nmol/L), respectively. Com-
pared with that during saline on day 1, the increment in the
plasma pancreatic polypeptide concentration during hy-
poglycemia was attenuated by ;50% on day 2 under all
three study conditions (P , 0.0001; Fig. 4). The pancreatic
polypeptide values during the last hour of hypoglycemia
were 373 6 6 pg/mL (89 6 1 pmol/L) on day 1 and 216 6 7
pg/mL (52 6 2 pmol/L), 214 6 17 pg/mL (51 6 4 pmol/L),
and 239 6 10 pg/mL (57 6 2 pmol/L), respectively, on day 2.
Plasma concentrations of infused insulin were stable
and comparable to those during saline on day 1 during all
three hyperinsulinemic euglycemic and hypoglycemic
clamps on day 2 (Fig. 5). Compared with that during saline
on day 1, the increments in the plasma glucagon concen-
trations during hypoglycemia were reduced under all three
conditions on day 2 (P = 0.0263, 0.0008 and ,0.0001, re-
spectively; Fig. 5). The glucagon values during the last
hour of hypoglycemia during saline infusion on day 1 were
99 6 1 pg/mL (28 6 0 pmol/L). The glucagon values during
the last hour of hypoglycemia on day 2 were 89 6 3 pg/mL
(26 6 1 pmol/L), 83 6 2 pg/mL (24 6 1 pmol/L), and 86 6 2
pg/mL (25 6 1 pmol/L) after saline, adrenergic blockade, and
adrenergic plus cholinergic blockade on day 1, respectively.
This was also the case for increments in the plasma
cortisol concentrations during hypoglycemia on day 2 (P =
0.0001, ,0.0001 and 0.0030) (Fig. 5). The cortisol values
during the last hour of hypoglycemia during saline infusion
on day 1 were 17.3 6 0.7 mg/dL (480 6 19 nmol/L). Cortisol
values during the last hour of hypoglycemia on day 2 were
14.2 6 0.6 mg/dL (390 6 17 nmol/L), 13.5 6 1.0 mg/dL
(370 6 28 nmol/L), and 15.0 6 1.1 mg/dL (410 6 30 nmol/L)
after saline, adrenergic blockade, and adrenergic plus
cholinergic blockade on day 1, respectively. Compared
with that during saline on day 1, the increment in the
plasma growth hormone concentration during hypoglyce-
mia was reduced on day 2 (P = 0.0028; Fig. 5). The growth
hormone values during the last hour of hypoglycemia were
12.6 6 0.5 ng/mL (560 6 22 pmol/L) on day 1 and 7.7 6 0.2
ng/mL (340 6 9 pmol/L) on day 2. In contrast, growth
hormone values during the last hour of hypoglycemia on
day 2 were not reduced after adrenergic blockade or ad-
renergic plus cholinergic blockade on day 1 210.8 6 0.8
ng/mL (480 6 35 pmol/L) and 14.0 6 1.4 ng/mL (620 6 62
pmol/L), respectively.
DISCUSSION
We used a well-documented model of HAAF in diabetes
(hypoglycemia attenuates the sympathoadrenal response
to hypoglycemia the following day) (1–4) and the classic
adrenergic and cholinergic antagonists phentolamine,
FIG. 3. Mean (6 SE) plasma insulin, glucagon, growth hormone, and
cortisol concentrations are shown during morning hyperinsulinemic
euglycemic and hypoglycemic clamps with intravenous infusions of sa-
line (○), phentolamine plus propranolol (□), or phentolamine plus
propranolol with atropine (△) on day 1. The P values represent com-
parisons with the values during saline, both P < 0.0001 for insulin,
growth hormone, and cortisol.
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that adrenergic activation, cholinergic activation, or both,
mediate the effect of recent antecedent hypoglycemia to
reduce the sympathoadrenal response to subsequent hy-
poglycemia, the key feature of HAAF in diabetes (1–8), in
humans.
The data indicate that adrenergic mechanisms mediate
the effect of recent antecedent hypoglycemia to reduce the
sympathoadrenal response to subsequent hypoglycemia.
Morning and afternoon hypoglycemia with saline infusion
on day 1 led to attenuated increments in plasma epineph-
rine and norepinephrine concentrations, markers of the
sympathoadrenal, primarily adrenomedullary, response to
hypoglycemia (17), during hypoglycemia on day 2. Thus, the
phenomenon that we sought to explore mechanistically—
recent antecedent hypoglycemia reduces the sympatho-
adrenal response to subsequent hypoglycemia (1–8)—was
reproduced.
However, when adrenergic blockade (without or with
cholinergic blockade) was produced during hypoglycemia
on day 1, the increments in plasma epinephrine and nor-
epinephrine concentrations during hypoglycemia on day 2
were not attenuated. Thus, combined adrenergic blockade
with the nonselective a-adrenergic antagonist phentol-
amine and the nonselective b-adrenergic antagonist pro-
pranolol prevented the effect of hypoglycemia to reduce the
FIG. 4. Mean (6 SE) plasma epinephrine, norepinephrine, and pan-
creatic polypeptide concentrations are shown during morning hyper-
insulinemic euglycemic and hypoglycemic clamps on day 1 with saline
infusion (○) and on day 2 after saline (●), phentolamine plus pro-
pranolol (PTL + PRP, ■), or phentolamine plus propranolol with atro-
pine (PTL + PRP + Atropine, ▲) during the clamps on day 1. The P
values represent comparisons with the values during saline infusion on
day 1 (○), P < 0.0001 for epinephrine and norepinephrine on day 2 (●),
and P < 0.0001 for pancreatic polypeptide under all three conditions on
day 2 (●, ■, and ▲).
FIG. 5. Mean (6 SE) plasma insulin, glucagon, growth hormone, and
cortisol concentrations are shown during morning hyperinsulinemic
euglycemic and hypoglycemic clamps on day 1 with saline infusion (○)
and on day 2 after saline (●), phentolamine plus propranolol (■), or
phentolamine plus propranolol with atropine (▲) during the clamps on
day 1. The P values represent comparisons with the values during saline
on day 1 (○); see text for details.
TABLE 1
Heart rate and blood pressure responses on day 1 during clamped hyperinsulinemic euglycemia (0800–0900 h) and hypoglycemia
(0900–1100 h)
Saline PTL + PRP PTL + PRP + Atropine
HR sBP dBP HR sBP dBP HR sBP dBP
Clock time (bpm) (mmHg) (mmHg) (bpm) (mmHg) (mmHg) (bpm) (mmHg) (mmHg)
0745 h 69 6 3 125 6 37 2 6 26 9 6 2 120 6 36 8 6 26 7 6 3 119 6 36 7 6 2
0800 h 68 6 2 125 6 37 1 6 27 0 6 2 118 6 46 6 6 26 9 6 3 118 6 36 8 6 2
0815 h 70 6 2 124 6 37 0 6 37 1 6 2 117 6 36 3 6 27 1 6 3 114 6 36 4 6 2
0830 h 71 6 3 125 6 37 0 6 27 2 6 2 115 6 36 0 6 16 9 6 3 112 6 36 4 6 2
0845 h 70 6 2 124 6 37 0 6 26 9 6 2 112 6 36 0 6 26 9 6 2 111 6 36 0 6 2
0900 h 71 6 2 124 6 36 8 6 26 8 6 2 113 6 35 8 6 17 7 6 4 112 6 35 9 6 2
0915 h 71 6 2 125 6 46 9 6 36 9 6 2 111 6 35 7 6 29 0 6 3 111 6 36 2 6 2
0930 h 72 6 3 124 6 46 8 6 36 7 6 2 110 6 35 7 6 28 6 6 3 113 6 36 0 6 2
0945 h 74 6 3 123 6 46 5 6 36 7 6 2 110 6 35 5 6 28 2 6 3 110 6 35 8 6 2
1000 h 76 6 3 126 6 46 4 6 26 6 6 2 108 6 25 3 6 18 2 6 2 109 6 35 7 6 2
1015 h 73 6 2 125 6 36 3 6 36 6 6 2 109 6 35 2 6 28 6 6 2 109 6 35 5 6 2
1030 h 73 6 2 122 6 46 1 6 36 3 6 2 105 6 35 2 6 18 4 6 2 106 6 35 3 6 2
1045 h 72 6 3 122 6 46 0 6 26 0 6 2 106 6 35 1 6 18 0 6 2 106 6 35 1 6 2
1145 h 73 6 3 119 6 46 0 6 26 0 6 2 106 6 35 1 6 17 7 6 2 105 6 35 1 6 2
P vs. saline ——— ,0.0001 ,0.0001 ,0.0001 ,0.0001 ,0.0001 ,0.0001
Values are mean 6 SE. dBP, diastolic blood pressure; HR, heart rate; sBP, systolic blood pressure; PTL, phentolamine; PRP, propranolol.
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The latter is the key feature of HAAF in diabetes (1–8).
T h ed a t ad on o td i s c l o s e —but do not categorically
exclude—an additional cholinergic mechanism. The
sympathoadrenal response to hypoglycemia on day 2 was
similar whether the muscarinic cholinergic antagonist at-
ropine was or was not administered with phentolamine
and propranolol during hypoglycemia on day 1.
Morning and afternoon hypoglycemia with saline in-
fusion on day 1 also led to attenuated increments in the
plasma pancreatic polypeptide concentration, a marker of
the parasympathetic response to hypoglycemia (18), dur-
ing hypoglycemia on day 2. In contrast to the effect on the
sympathoadrenal response, adrenergic blockade (without
or with cholinergic blockade) during hypoglycemia on day
1 did not prevent the attenuated pancreatic polypeptide
response to hypoglycemia on day 2. An altered para-
sympathetic response is not known to be involved in the
pathogenesis of HAAF in diabetes (1).
To the extent the drugs used enter the central nervous
system (propranolol and atropine are known to do so), the
data do not distinguish between central and peripheral
(autonomic) nervous system mediation of the effect of an-
tecedent hypoglycemia to reduce the sympathoadrenal re-
sponse to subsequent hypoglycemia. However, because the
adrenergic antagonists block the heart rate and pressor
responses to hypoglycemia, which are normally mediated
by the autonomic response, one might speculate that it was
blockade of adrenergic sympathoadrenal actions during
hypoglycemia on day 1 that prevented an attenuated plasma
catecholamine response to hypoglycemia on day 2.
The data conﬁrm substantially higher plasma epineph-
rine and norepinephrine concentrations in response to
hypoglycemia during adrenergic blockade on day 1 (15).
That is expected because both catecholamines are cleared
through b-adrenergic mechanisms in humans (19). (Given
the short half-times of the antagonists and the catechol-
amines, a carry-over effect to the next day is unlikely.) The
current ﬁndings of higher plasma concentrations of in-
fused insulin and of endogenous growth hormone and
cortisol during hypoglycemia during adrenergic blockade
suggest that adrenergic mechanisms are also involved in
the clearance of these hormones. The growth hormone
responses to hypoglycemia, like the epinephrine and nor-
epinephrine responses, were reduced after hypoglycemia
with saline infusion but not after hypoglycemia with ad-
renergic blockade (without or with cholinergic blockade).
An interesting ﬁnding was that the pancreatic polypeptide,
glucagon, and cortisol responses to hypoglycemia were
reduced on day 2 regardless of the day 1 conditions.
Among these, a reduced glucagon response is a feature of
HAAF (1). Thus, the data further support the view that the
mechanisms of the reduced glucagon and epinephrine
responses to hypoglycemia in HAAF are different (1).
In conclusion, the data indicate that adrenergic mecha-
nisms mediate the effect of recent antecedent hypoglycemia
to reduce the sympathoadrenal response to subsequent hy-
poglycemia, the key feature of HAAF in diabetes, in humans.
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